Equities research analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report sales of $3.00 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Seres Therapeutics’ earnings. Seres Therapeutics posted sales of $3.04 million in the same quarter last year, which suggests a negative year-over-year growth rate of 1.3%. The business is expected to announce its next earnings results on Thursday, March 15th.
According to Zacks, analysts expect that Seres Therapeutics will report full year sales of $3.00 million for the current year, with estimates ranging from $29.04 million to $32.04 million. For the next financial year, analysts expect that the company will post sales of $20.09 million per share, with estimates ranging from $12.00 million to $29.30 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.22. The company had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The firm’s revenue was up 76.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.46) EPS.
A number of equities analysts recently commented on MCRB shares. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. HC Wainwright reissued a “buy” rating and issued a $19.00 price target (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Zacks Investment Research lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, BidaskClub lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. Seres Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.00.
Shares of Seres Therapeutics (MCRB) traded up $0.13 during trading hours on Friday, reaching $9.54. 42,958 shares of the company were exchanged, compared to its average volume of 177,785. Seres Therapeutics has a one year low of $8.85 and a one year high of $17.42. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53.
A number of institutional investors have recently made changes to their positions in MCRB. Cubist Systematic Strategies LLC bought a new stake in shares of Seres Therapeutics during the 3rd quarter valued at about $170,000. Perceptive Advisors LLC bought a new stake in shares of Seres Therapeutics during the 3rd quarter valued at about $2,165,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Seres Therapeutics by 12.8% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 103,286 shares of the biotechnology company’s stock valued at $1,657,000 after purchasing an additional 11,743 shares in the last quarter. Schroder Investment Management Group bought a new stake in shares of Seres Therapeutics during the 3rd quarter valued at about $1,088,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Seres Therapeutics by 39.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after purchasing an additional 106,479 shares in the last quarter. 77.04% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “$3.00 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/11/26/3-00-million-in-sales-expected-for-seres-therapeutics-inc-mcrb-this-quarter.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.